Case Report

Clinical Rheumatology

, Volume 25, Issue 5, pp 749-752

First online:

Rasburicase treatment in severe tophaceous gout: a novel therapeutic option

  • J. D. MoolenburghAffiliated withDepartment of Rheumatology, Medical Centre Alkmaar Email author 
  • , M. K. ReindersAffiliated withDepartment of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden
  • , T. L. Th. A. JansenAffiliated withDepartment of Rheumatology, Medical Centre Leeuwarden

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


We recently encountered a destructive case of tophaceous gout in a 57-year-old patient. Despite perfect therapy compliance, the patient failed in the conventional urate-lowering treatment, accounting for the ongoing urate retention and accumulation with progressive tophaceous bulky disease. Application of an experimental scheme of uricolytical therapy on this patient was able to reduce bulky disease significantly. In modern medicine, potent urate-debulking medication with urate oxidase (uricase) derivatives is at our disposal, and it is a challenge for rheumatologists to install the right strategy including innovative approaches with potent uricolytic therapy on the right patient at the right time.


Gout Rasburicase Review Urate oxidase